Recent Company News

• 04:23 PM ET Jun 17, 2026
  

  GSK announces Utebzi approved in the US for adults with complicated urinary tract infections (cUTIs) (1973.0000p, 0)

• 12:39 PM ET Jun 17, 2026
  

  Spero Therapeutics issues press release on FDA approval of Utebzi (tebipenem pivoxil) tablets for the treatment of cUTI ($2.29, -0.49)

• 09:57 AM ET Jun 17, 2026
  

  Follow-up: FDA approves Utebzi (tebipenem pivoxil) tablets for the treatment of cUTI ($2.69, -0.09)

• 09:55 AM ET Jun 17, 2026
  

  FDA approves Utebzi (tebipenem pivoxil) tablets for the treatment of cUTI ($2.69, -0.09)

• 08:49 AM ET Jun 17, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:05 PM ET Jun 16, 2026
  

  NICE recommends GSK's Nucala for maintenance treatment of uncontrolled COPD with raised blood eosinophils (1950.0000p, 0)

• 05:17 PM ET Jun 16, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:00 PM ET Jun 16, 2026
  

  Health Canada approves two new indications for Exdensur, severe asthma and CRSwNP (earlier, 12:13ET) (1950.0000p, 0)

• 01:17 PM ET Jun 15, 2026
  

  Market Voices: Value Investing with Legends with Jim Flynn, Managing Partner of Deerfield Management, on healthcare innovation, AI, and long-term investing

• 09:33 AM ET Jun 15, 2026
  

  StreetAccount M&A Summary: Week of 8-Jun